HeartBeam (Nasdaq:BEAT) announced today that the U.S. Patent and Trademark Office issued a patent for its 12-lead electrocardiogram (ECG) patch.
Santa Clara, California–based HeartBeam designed its ECG patch monitor for detecting acute coronary syndrome (ACS) and cardiac arrhythmia.
The company said in a news release that the granted patent builds on its portfolio, enabling 12-lead ECG diagnostics outside the medical setting. HeartBeam’s ECG can aid physicians in arrhythmia detection and ACS diagnosis that includes heart attack and angina.
“This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and founder Branislav Vajdic. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability.”
The newly issued patent (No. 11,419,538 B2) expands on HeartBeam’s previously granted U.S. patent (No. 11,071,490 B1) for a 12-lead ECG patch monitor technology.
HeartBeam said the patch patent comes on the back of its core patents for remote heart attack detection. Altogether, it believes the issued patents increase its intellectual property footprint. HeartBeam feels that they widen the impact that its technology could have on cardiac patients and physicians.
“The ECG monitors available today are primarily used for detection of abnormal heart rhythms associated with atrial fibrillation or syncope,” said Martin Burke cardiac electrophysiologist and chief scientific officer of the CorVita Science Foundation. “A 12-lead ECG patch would provide additional information to aid in diagnosing conditions such as ACS or more specific arrhythmias that current single-lead patches cannot accurately detect.”
